This Phase 2 trial tests whether adding the experimental drug casdozokitug to a standard immunotherapy combination (toripalimab plus bevacizumab) can safely shrink tumors in people with advanced liver cancer that cannot be removed by surgery. The study enrolls 72 participants and…
Phase: PHASE2 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC